carbidopa
E804842
Carbidopa is a medication used in combination with levodopa to treat Parkinson’s disease by preventing peripheral breakdown of levodopa and reducing its side effects.
All labels observed (1)
| Label | Occurrences |
|---|---|
| carbidopa canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T9524764 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: carbidopa Context triple: [levodopa, oftenCombinedWith, carbidopa]
-
A.
levodopa
Levodopa is a cornerstone medication for managing Parkinson’s disease symptoms by replenishing the brain’s depleted dopamine levels.
-
B.
entacapone
Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct medication in Parkinson’s disease therapy to prolong and enhance the effects of levodopa.
-
C.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
D.
pimozide
Pimozide is a typical antipsychotic medication primarily used to treat Tourette’s disorder and severe tics.
-
E.
Namenda
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: carbidopa Target entity description: Carbidopa is a medication used in combination with levodopa to treat Parkinson’s disease by preventing peripheral breakdown of levodopa and reducing its side effects.
-
A.
levodopa
Levodopa is a cornerstone medication for managing Parkinson’s disease symptoms by replenishing the brain’s depleted dopamine levels.
-
B.
entacapone
Entacapone is a catechol-O-methyltransferase (COMT) inhibitor used as an adjunct medication in Parkinson’s disease therapy to prolong and enhance the effects of levodopa.
-
C.
rivastigmine
Rivastigmine is a cholinesterase inhibitor medication used to manage symptoms of mild to moderate dementia, particularly in Alzheimer's and Parkinson's disease.
-
D.
pimozide
Pimozide is a typical antipsychotic medication primarily used to treat Tourette’s disorder and severe tics.
-
E.
Namenda
Namenda is a prescription medication used to treat moderate to severe Alzheimer's disease by regulating the activity of glutamate in the brain.
- F. None of above. chosen
Statements (48)
| Predicate | Object |
|---|---|
| instanceOf |
antiparkinsonian agent
ⓘ
decarboxylase inhibitor ⓘ pharmaceutical drug ⓘ small molecule ⓘ |
| actsOn | aromatic L-amino acid decarboxylase ⓘ |
| belongsToClass | hydrazine derivatives ⓘ |
| bioavailability | about 40–70% ⓘ |
| commonAdverseEffect |
dizziness
ⓘ
dry mouth ⓘ dyskinesia (when combined with levodopa) ⓘ nausea ⓘ orthostatic hypotension ⓘ |
| contraindicatedWith | nonselective MAO inhibitors ⓘ |
| developedFor | enhancing levodopa therapy ⓘ |
| doesNotCross | blood–brain barrier effectively ⓘ |
| eliminationHalfLife | about 1.5–2 hours ⓘ |
| firstApprovalDecade | 1970s GENERATED ⓘ |
| firstApprovedIn | United States NERFINISHED ⓘ |
| hasATCCode | N04BA02 ⓘ |
| hasCASNumber | 28860-95-9 ⓘ |
| hasChemicalFormula | C10H14N2O4 ⓘ |
| hasDrugBankID | DB00190 ⓘ |
| hasIUPACName | (2S)-3-(3,4-dihydroxyphenyl)-2-hydrazino-2-methylpropanoic acid ⓘ |
| hasMolarMass | 226.23 g/mol ⓘ |
| hasPubChemCID | 34359 ⓘ |
| hasStereochemistry | L-enantiomer is active form ⓘ |
| increases | central nervous system availability of levodopa ⓘ |
| isComponentOf |
Parcopa
NERFINISHED
ⓘ
Rytary NERFINISHED ⓘ Sinemet NERFINISHED ⓘ carbidopa/levodopa combination product ⓘ |
| isListedOn | World Health Organization Model List of Essential Medicines NERFINISHED ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| mayCause |
confusion (with levodopa)
ⓘ
hallucinations (with levodopa) ⓘ |
| mechanismOfAction | inhibits peripheral aromatic L-amino acid decarboxylase ⓘ |
| pregnancyCategoryUS | C ⓘ |
| primaryEliminationRoute | renal GENERATED ⓘ |
| proteinBinding | about 36% ⓘ |
| reduces |
levodopa-induced cardiovascular side effects
ⓘ
levodopa-induced nausea ⓘ levodopa-induced vomiting ⓘ peripheral metabolism of levodopa ⓘ |
| routeOfAdministration | oral ⓘ |
| treats |
Parkinson's disease
NERFINISHED
ⓘ
Parkinsonian syndrome NERFINISHED ⓘ |
| usedInCombinationWith | levodopa ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: carbidopa Description of subject: Carbidopa is a medication used in combination with levodopa to treat Parkinson’s disease by preventing peripheral breakdown of levodopa and reducing its side effects.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.